Kailera Therapeutics Inc. (KLRA.US), a clinical-stage biotechnology company focused on obesity treatments, has successfully raised $625 million by increasing the size of its initial public offering. This marks the largest IPO in the U.S. biotech sector since 2021. The Waltham, Massachusetts-based company priced its IPO at the top end of its previously announced range. According to a statement released on Thursday, Kailera sold approximately 39 million shares at $16 per share. The company had initially planned to offer 33.3 million shares within a price range of $14 to $16 per share. People familiar with the matter indicated the offering was oversubscribed by a double-digit multiple. At the IPO price, Kailera's market valuation is approximately $2 billion, based on the number of shares outstanding listed in its prospectus.

This listing represents the largest biotech IPO in the U.S. since 2021, surpassing the previous record set by cell engineering firm Sana Biotechnology Inc. (SANA.US), which raised $676 million that year. Kailera is entering an increasingly competitive drug development landscape, with multiple pharmaceutical companies vying for a share of the obesity treatment market, which is projected to reach $200 billion by 2030. Eli Lilly (LLY.US) and Novo Nordisk (NVO.US) currently lead the field with FDA-approved weight-loss drugs, including both oral and injectable formulations.

Founded in 2024, Kailera is a late-stage biotech company developing four GLP-1-based obesity treatments. These include a once-weekly injectable and a once-daily oral pill, both of which are currently in advanced clinical trials. Existing shareholders, including Bain Capital Private Equity, Bain Capital Life Sciences, and the Qatar Investment Authority, have expressed interest in purchasing up to $225 million of the company's stock at the IPO price. According to the prospectus, affiliates of Bain Capital will hold approximately one-third of the company's shares following the offering.

Financially, Kailera reported a net loss of $149 million for the fiscal year ending December 2025. For the period from its inception in May 2024 through December 2024, the company recorded a net loss of $219.7 million. The company is led by Ronald Renaud, former CEO of Cerevel Therapeutics, which was acquired by AbbVie (ABBV.US) for $8.7 billion in 2024. Prior to this IPO, Kailera raised $600 million in a Series B financing round in October of last year. That round was led by Bain Capital Private Equity and included new investors such as Janus Henderson Investors, Surveyor Capital, and Invus, alongside participation from existing investors Atlas Venture, Bain Capital Life Sciences, and Sirona Capital.

Lead underwriters for the offering include J.P. Morgan, Jefferies, Leerink Partners LLC, Cowen Inc., and Evercore Inc. The company's shares are expected to begin trading on the Nasdaq Global Market on Friday under the ticker symbol "KLRA."